OPKO Health Management
Management criteria checks 3/4
OPKO Health's CEO is Phil Frost, appointed in Mar 2007, has a tenure of 17.67 years. total yearly compensation is $2.28M, comprised of 42.2% salary and 57.8% bonuses, including company stock and options. directly owns 35.94% of the company’s shares, worth $387.59M. The average tenure of the management team and the board of directors is 9.7 years and 15.6 years respectively.
Key information
Phil Frost
Chief executive officer
US$2.3m
Total compensation
| CEO salary percentage | 42.2% |
| CEO tenure | 17.7yrs |
| CEO ownership | 35.9% |
| Management average tenure | 9.7yrs |
| Board average tenure | 15.6yrs |
Recent management updates
Recent updates
OPKO Health, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Nov 09
Not Enough To Keep OPKO Health Flying
Aug 28OPKO Health, Inc. (NASDAQ:OPK) Not Flying Under The Radar
Dec 30Is OPKO Health (NASDAQ:OPK) A Risky Investment?
Oct 03OPKO Health, Inc.'s (NASDAQ:OPK) 28% Share Price Surge Not Quite Adding Up
Jul 24Would OPKO Health (NASDAQ:OPK) Be Better Off With Less Debt?
Jun 07Is OPKO Health (NASDAQ:OPK) Using Too Much Debt?
Jan 04OPKO Health: Assessing If Significant Potential Can Be Realized
Sep 15OPKO Health (NASDAQ:OPK) Is Carrying A Fair Bit Of Debt
Sep 05OPKO Health: 14%+ Short Interest Means More Volatility Over The Near Term
Jun 21OPKO Health (NASDAQ:OPK) Is Carrying A Fair Bit Of Debt
Apr 29OPKO Health: A Great Long-Term Investment In Health
Apr 05OPKO Health Is Risky But Might Make You Money
Mar 29CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$134m |
| Jun 30 2024 | n/a | n/a | -US$243m |
| Mar 31 2024 | n/a | n/a | -US$252m |
| Dec 31 2023 | US$2m | US$960k | -US$189m |
| Sep 30 2023 | n/a | n/a | -US$208m |
| Jun 30 2023 | n/a | n/a | -US$209m |
| Mar 31 2023 | n/a | n/a | -US$291m |
| Dec 31 2022 | US$972k | US$960k | -US$328m |
| Sep 30 2022 | n/a | n/a | -US$317m |
| Jun 30 2022 | n/a | n/a | -US$202m |
| Mar 31 2022 | n/a | n/a | -US$117m |
| Dec 31 2021 | US$2m | US$960k | -US$30m |
| Sep 30 2021 | n/a | n/a | US$76m |
| Jun 30 2021 | n/a | n/a | US$71m |
| Mar 31 2021 | n/a | n/a | US$121m |
| Dec 31 2020 | US$2m | US$960k | US$31m |
| Sep 30 2020 | n/a | n/a | -US$114m |
| Jun 30 2020 | n/a | n/a | -US$200m |
| Mar 31 2020 | n/a | n/a | -US$293m |
| Dec 31 2019 | US$1m | US$960k | -US$315m |
| Sep 30 2019 | n/a | n/a | -US$279m |
| Jun 30 2019 | n/a | n/a | -US$244m |
| Mar 31 2019 | n/a | n/a | -US$191m |
| Dec 31 2018 | US$2m | US$960k | -US$153m |
| Sep 30 2018 | n/a | n/a | -US$295m |
| Jun 30 2018 | n/a | n/a | -US$303m |
| Mar 31 2018 | n/a | n/a | -US$314m |
| Dec 31 2017 | US$971k | US$960k | -US$305m |
Compensation vs Market: Phil's total compensation ($USD2.28M) is about average for companies of similar size in the US market ($USD3.17M).
Compensation vs Earnings: Phil's compensation has increased whilst the company is unprofitable.
CEO
Phil Frost (88 yo)
17.7yrs
Tenure
US$2,277,200
Compensation
Dr. Phillip Frost, also known as Phil, M.D., Ph D., is Director of Non-Invasive Monitoring Systems, Inc. since June 01, 2023. He has been the Chairman, Chief Executive Officer and Director of OPKO Health,...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 17.7yrs | US$2.28m | 35.94% $ 387.6m | |
| Vice Chairman & Chief Technical Officer | 17.8yrs | US$2.19m | 4.85% $ 52.3m | |
| President & Vice Chairman | 2.5yrs | US$2.19m | 2.99% $ 32.3m | |
| Senior VP | 17.7yrs | US$1.81m | 0.026% $ 283.1k | |
| Executive VP of Administration & Director | 17.5yrs | US$1.94m | 0.91% $ 9.8m | |
| Senior Vice President of Clinical Research & Development and Medical Affairs - Opko Renal | 7.7yrs | no data | no data | |
| Chief Innovation Officer & Director | 2.5yrs | no data | 5.91% $ 63.7m | |
| Chief Medical Officer | less than a year | no data | no data | |
| Chief Executive Officer of OPKO Renal | 11.7yrs | no data | no data | |
| President of Transition Therapeutics | no data | no data | no data | |
| President of OPKO Health Iberoamerica | no data | no data | no data | |
| Chief Executive Officer of EirGen Pharma | 5yrs | no data | no data |
9.7yrs
Average Tenure
71.5yo
Average Age
Experienced Management: OPK's management team is seasoned and experienced (9.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 17.7yrs | US$2.28m | 35.94% $ 387.6m | |
| Vice Chairman & Chief Technical Officer | 17.8yrs | US$2.19m | 4.85% $ 52.3m | |
| President & Vice Chairman | 2.5yrs | US$2.19m | 2.99% $ 32.3m | |
| Executive VP of Administration & Director | 17.8yrs | US$1.94m | 0.91% $ 9.8m | |
| Chief Innovation Officer & Director | 2.5yrs | no data | 5.91% $ 63.7m | |
| Independent Director | 3.9yrs | US$69.90k | 0% $ 0 | |
| Lead Independent Director | 16.8yrs | US$134.80k | 0.048% $ 513.5k | |
| Independent Director | 7.8yrs | US$92.40k | 0.015% $ 163.3k | |
| Independent Director | 20.9yrs | US$84.90k | 0.058% $ 621.8k | |
| Independent Director | 3.7yrs | US$92.40k | 0% $ 0 | |
| Independent Director | 15.6yrs | US$62.40k | 0.0097% $ 105.0k |
15.6yrs
Average Tenure
77yo
Average Age
Experienced Board: OPK's board of directors are seasoned and experienced ( 15.6 years average tenure).